Keys to recovery include early diagnosis and timely antiviral therapy to alleviate symptoms, decrease disease severity, and reduce the risk of any corneal complications that could adversely affect the patient’s eyesight.^1,2
 
Initial treatment for HSV dendritic keratitis typically involves topical antiviral agents. The authors choose ganciclovir gel, FDA-approved in 2009, as their preferred first-line topical medication due to its safety, efficacy, and tolerability profile.³

In a new white paper, Dr. Christopher Rapuano and Dr. Joseph Shovlin discuss their preferred treatment options.


References: 1. Lobo AM, Agelidis AM, Shukla D. Pathogenesis of herpes simplex keratitis: the host cell response and ocular surface sequetae to infection and inflammation. Ocul Surf. 2019;17(1):4049. 2. White ML, Chodosh J. Herpes simplex virus keratitis: a treatment guideline-2014. Accessed March 19, 2021. https://www.aao.org/clinical-statementlherpes-simplex-virus-keratitis-treatment - guideline. 3. Chou TY, Hong BY. Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications. Ther Clin Risk Manag. 2014;10:665-681.

Sponsored By